Table 3.
Overall survival in groups without or with adjuvant chemotherapy
| No adjuvant chemotherapy group | Adjuvant chemotherapy group | |||||
|---|---|---|---|---|---|---|
| |
No. (%) |
5-Y OS rate (%) |
P |
No. (%) |
5-Y OS rate (%) |
P |
| All patients |
36 (100) |
68.3 |
|
57 (100) |
52.3 |
|
| ERCC1 status |
|
|
0.083 |
|
|
0.074 |
| Positive |
20 (55.6) |
84.0 |
|
34 (59.6) |
41.6 |
|
| Negative |
16 (44.4) |
49.2 |
|
23 (40.4) |
71.8 |
|
| Sex |
|
|
0.080 |
|
|
0.14 |
| Male |
32 (88.9) |
70.6 |
|
47 (82.5) |
46.2 |
|
| Female |
4 (11.1) |
50.0 |
|
10 (17.5) |
77.8 |
|
| Age at operation |
|
|
0.40 |
|
|
0.99 |
| ≥ 65 years |
24 (66.7) |
70.0 |
|
16 (28.1) |
60.3 |
|
| < 65 years |
12 (33.3) |
61.1 |
|
41 (71.9) |
51.2 |
|
| T stage |
|
|
0.21 |
|
|
0.57 |
| T1-T2 |
15 (41.7) |
83.6 |
|
4 (7.0) |
50.0 |
|
| T3-T4 |
21 (58.3) |
59.2 |
|
53 (93.0) |
52.9 |
|
| N stage |
|
|
0.10 |
|
|
0.73 |
| N0 |
32 (88.9) |
70.9 |
|
29 (50.9) |
47.7 |
|
| N1-3 |
4 (11.1) |
50.0 |
|
28 (49.1) |
59.1 |
|
| Histologic type |
|
|
0.088 |
|
|
0.21 |
| Squamous differentiation |
2 (5.6) |
50.0 |
|
9 (15.8) |
77.8 |
|
| Other types |
34 (94.4) |
69.8 |
|
48 (84.2) |
46.8 |
|
| Pathologic Grade* |
|
|
0.35 |
|
|
0.47 |
| G2 |
3 (8.3) |
100.0 |
|
7 (12.3) |
71.4 |
|
| G3 | 33 (91.7) | 65.7 | 50 (87.7) | 50.2 | ||
*1973 WHO grading.